European Respiratory Journal

Article	Citations
The right ventricle tamed	1675
Unravelling the “frequent exacerbator” phenotype in cystic fibrosis	1086
Chymase-1: a “MAST”-er switch in COPD?	379
If your patient with asthma wheezes when sitting or lying quietly, lung function testing may reveal small airway disease	312
Missing airways, ventilation defects and conductive airway physiology in asthma	220
Epigenome-wide association studies: the exposures of yesterday form the methylations of tomorrow	219
A breath of the future: a novel human model for COPD and beyond	212
The lung that rules the heart	185
Randomised controlled trials utilisingFENOto manage asthma: is it time to acknowledge that “one size does not fit all”?	152
Lymphoma in patients with asthma treated with dupilumab: much ado about nothing?	142
Novel pathomechanisms of ventilator-induced neonatal lung injury: new targets to overcome ongoing challenges	139
From spatial transcriptomics to mouse model: the (re-)emergence of ductal myofibroblasts as a new cellular target in idiopathic pulmonary fibrosis	139
Natural decline in pulmonary function following bilateral lung transplantation: a single-centre study	138
Gene–environment interaction at 17q12–q21 locus and its role in asthma pathogenesis	137
Plasma cells: a feasible therapeutic target in pulmonary fibrosis?	132
Soteria: deliverance from harm?	124
Prenatal exposure to greenness and early childhood pneumonia: a nationwide study in Japan	122
Invisibility of breathlessness in clinical consultations: a cross-sectional, national online survey	121
Associations between High-Density Lipoprotein Cholesterol and Interstitial Lung Abnormalities in the Korean National Lung Cancer Screening	120
Shear-wave elastography-guided transthoracic biopsy for lung lesions: a randomised controlled trial	120
Arousal threshold modifies the effect of CPAP on executive function among individuals with obstructive sleep apnoea	114
Fibroblast heterogeneity in pulmonary fibrosis: a new target for therapeutics development?	112
Pleural fluid proteomics from patients with pleural infection shows signatures of diverse neutrophilic responses: The Oxford Pleural Infection Endotyping Study (TORPIDS-2)	112
Moving the needle on proteasome inhibitor-induced pulmonary arterial hypertension: a definite maybe	107
A patient-tailored approach for corticosteroid treatment in COVID-19: still not there yet	106

A normal BNP does not reliably exclude pulmonary hypertension in interstitial lung disease	104
Haemodynamic phenotypes of pulmonary hypertension associated with left heart disease: a moving target	102
Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long-COVID symptoms	102
Pirfenidone in post-COVID-19 pulmonary fibrosis (FIBRO-COVID): a phase 2 randomised clinical trial	101
Cystic fibrosis macrophage function and clinical outcomes after elexacaftor/tezacaftor/ivacaftor	100
sST2 and IL-6 predict prognosis of medically treated chronic thromboembolic pulmonary hypertension	100
Repositioning of ezetimibe for the treatment of idiopathic pulmonary fibrosis	94
Combining rituximab with mycophenolate for the treatment of interstitial lung disease	93
RIPK1 kinase-dependent inflammation and cell death contribute to the pathogenesis of COPD	91
Tricuspid regurgitation in pulmonary arterial hypertension: a right ventricular volumetric and functional analysis	89
Idiopathic pleuroparenchymal fibroelastosis: three-dimensional computed tomography assessment of upper-lobe lung volume	85
Pulmonary hypertension associated with hereditary haemorrhagic telangiectasia: from genetics to clinical management	84
Extensive acute and sustained changes to neutrophil proteomes post-SARS-CoV-2 infection	84
Revisiting asthma pharmacotherapy: where do we stand and where do we want to go?	82
Collaboration between explainable artificial intelligence and pulmonologists improves the accuracy of pulmonary function test interpretation	81
Salivary polyreactive antibodies andHaemophilus influenzaeare associated with respiratory infection severity in young children with recurrent respiratory infections	81
Antiviral CD8+T-cell immune responses are impaired by cigarette smoke and in COPD	78
Long-term radiological and pulmonary function abnormalities at 3 years after COVID-19 hospitalisation: a longitudinal cohort study	78
Treatment algorithm for pulmonary arterial hypertension	75
Risk of rifampicin resistance emergence after incomplete first-line tuberculosis treatment	72
No exposure left behind: time to pay attention to children's chemical environment in lung development	72
The impact of oral anticoagulants on idiopathic pulmonary fibrosis risk and prognosis: a population study	72
Exciting times for trimodulin	69
Challenges in harmonising terms and patterns among interstitial pneumonias: enter idiopathic bronchiolocentric interstitial pneumonia	69
The limits of normal of pulmonary arterial wedge pressure	68
Small packages but big insights: extracellular vesicles as biomarkers in interstitial lung disease associated with systemic sclerosis	68
Reply: Tuberculosis screening in migrants to the EU/EEA and UK	64
Are intravenous corticosteroid pulses superior to low dose corticosteroids in patients with severe COVID-19?	64
Selexipag for inoperable CTEPH: why meeting a primary endpoint simply isn't enough	63
CPAP recall and cancer risk: should we be concerned?	62
Response from the authors: As-needed ICS/formoterol or as-needed SABA in mild asthma?	62
FEV1Q: what (even) is normal lung function?	61
Trends in COVID-19-associated mortality in patients with pulmonary hypertension: a COMPERA analysis	61
The risk of hypoventilation during bronchoscopy under oxygen and procedural sedation	61
Azithromycin enhances epithelial antiviral immunity in uncontrolled asthma: results from the AZIMUNE randomized controlled trial	60
Single-inhaler tripleversusdual bronchodilator therapy for GOLD group E and other exacerbating patients with COPD: real-world comparative effectiveness and safety	60
Sputum metagenomics in bronchiectasis reveals pan-European variation: an EMBARC-BRIDGE study	60
Particulate matter-related ITIH4 deficiency is associated with an emphysema phenotype of COPD through JNK-dependent and JNK-independent signalling	58
The association between immunosuppressants and outcomes of COVID-19	56
Immunogenicity and safety of coadministration of COVID-19 and influenza vaccination	56
Lunsekimig's bispecific targeting of IL-13 and TSLP in asthma: dual targets for synergistic effects?	55
End-user global study to identify countries’ challenges and solutions in the uptake and implementation of new tuberculosis treatment regimens	55
Real-world monitoring of elexacaftor/tezacaftor/ivacaftor trough concentrations in adults with cystic fibrosis	54
Genomic classifier for usual interstitial pneumonia combined with bronchoalveolar lavage cellular profile: potential use in the clinical management of new onset ILD?	54
The vascular fingerprint of the lungs: why pulmonary vessel count matters in COPD	54
Rethinking smoking cessation guidelines in patients with obstructive sleep apnoea: a survey of sleep experts from the ESADA network	52
WHO online guide on the use of digital technologies for tuberculosis programmes	52
Associations of hiatus hernia with CT-based interstitial lung changes: the MESA Lung Study	52
Leukocytic ADAM10 and ADAM17 modulate disease severity and systemic outcome in bacterial and viral pneumonia	52
“Age-related changes in plasma biomarkers and their association with mortality in COVID-19.” E.H.A. Michels, B. Appelman, J. de Brabander, et al .	52

Pulmonary hypertension in patients with Noonan syndrome	51
List of European Respiratory Journal peer reviewers 2023	51
Clinical, physiological, imaging and molecular responses to cannabis smoking: the Canadian Users of Cannabis Smoke (CANUCK) study	51
The association of eicosanoids and eicosanoid-related metabolites with pulmonary hypertension	50
Inhaled recombinant GM-CSF reduces the need for whole lung lavage and improves gas exchange in autoimmune pulmonary alveolar proteinosis patients	50
Pleural mesothelioma: surgery questioned again?	49
Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme	48
Cystic fibrosis in Europe: improved lung function and longevity – reasons for cautious optimism, but challenges remain	47
Distribution of Blood Eosinophil Count in the Chinese General Population	47
Reading the monocyte code in idiopathic pulmonary fibrosis	46
Theratyping in cystic fibrosis: filling the knowledge gaps	46
Early-life exposure to a mixture of phenols and respiratory health in preschool children	45
Inflammatory stimuli and the rescue of disease-causing CFTR nonsense variants	45
Treat-and-repair: a simple but powerful term for a complex multimodal approach in patients with pulmonary arterial hypertension associated with congenital heart disease	44
Vocal cord paralysis as a rare complication of bronchoscopic lung volume reduction: a case series of five patients	44
Comment on: Combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with COPD: a systematic review and meta-analysis	44
COVID-19 changed the world – without changing CTEPH	43
Let's talk about sex… in pulmonary fibrosis	43
Multitasking within the airway epithelium	43
Filters used for pulmonary function testing	43
Contributions to simplifying the global interpretation of spirometry: high quality spirometry data from Asia	43
Bronchoconstriction with inhaled ATP in healthy volunteers	43
Prolonged higher dose methylprednisoloneversusconventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS)	42
Muscle sympathetic nerve activity and adaptive servo-ventilation: questions remain	42
ERJ Podcast January 2026: Cannabis and the lung	42
“Lung function trajectories in South African children with pulmonary tuberculosis compared to those with non-TB lower respiratory tract infection: a prospective study.” D.M. Gray, L. Githinji, K. Brit	41
Respective roles of non-pharmaceutical interventions in bronchiolitis outbreaks: an interrupted time-series analysis based on a multinational surveillance system	41
An attack of asthma is not an attack of the heart: clarifying causal links between asthma and incident coronary heart disease	40
Skewed adaptive immune responses are involved in alpha-1 antitrypsin deficiency emphysema	40
Efficacy and safety of cladribine in adult pulmonary Langerhans cell histiocytosis: a phase II study	40
Reply to: HIV-TB risk factor assessment in Europe: methodological considerations and clinical implications	40
Cardiopulmonary response to exercise in adults born very preterm	40
Reply: The new ERS/ATS standards on lung function test interpretation: some extant limitations	40
Unbowed, unbent, unbroken: predicting pulmonary hypertension using echocardiography	40
Transcriptomic clustering of critically ill COVID-19 patients	40
Impact of the expanded label for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del variant in the USA	39
Small extracellular vesicles and induction of epithelial-to-mesenchymal transition in lymphangioleiomyomatosis	39
The proteomic landscape of blood monocytes in community-acquired pneumonia	39
Risk assessment of systemic sclerosis-associated pulmonary arterial hypertension: cardiac index versus stroke volume index	38
ERJ Podcast October 2023: ERS short guidelines for the use of as-needed ICS/formoterol in mild asthma	38
Right ventricular–pulmonary arterial coupling and its relationship to exercise haemodynamics in a continuum of patients with pulmonary vascular disease due to chronic thromboembolism	38
ERJ Podcast January 2024: The microbiome in early life and childhood asthma	38
Oral corticosteroids in asthma and beyond: moving forward	38
Epigenetic age among US adults with chronic respiratory diseases: results from NHANES 1999–2002	37
Air pollution and COPD: GOLD 2023 committee report	37
MK-5475, an inhaled soluble guanylate cyclase stimulator, for treatment of pulmonary arterial hypertension: the INSIGNIA-PAH study	37
Heart rate response and cardiovascular risk during obstructive sleep apnoea: an easy biomarker derived from pulse oximetry	37
Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension	37
Airflow-based prediction of lateral wall collapse: advancing personalised hypoglossal nerve stimulation in obstructive sleep apnoea	36
Peripheral pulmonary artery stenosis in adults: a novel type of pulmonary vascular disease with a strong genetic background	36
Tracing the origins of fibrotic fibroblasts: does the name matter? Look at the genes!	36
ERJPodcast January 2025: Treatment response to mepolizumab in severe eosinophilic asthma	36
Primary spontaneous pneumothorax: does size matter?	36
Reply to: Pirfenidone and lung cancer in idiopathic pulmonary fibrosis: mind the index date, detection bias and competing risks	36
Presenting clinical data for the hazard classification of chemical respiratory sensitisers	36
Reply to: Towards causal validation and clinical translation of the PAK2–fibroblast axis in idiopathic pulmonary fibrosis	35
Lung structure and longitudinal change in cardiac structure and function: the MESA COPD Study	35
Decoding the eosinophil connection: implications for precision treatment of emphysematous in COPD	35
Commentary on: Update of the international multidisciplinary classification of the interstitial pneumonias: an ERS/ATS statement	35
The COVID-19 pandemic and pulmonary arterial hypertension in Italy: adaptation, outcomes and valuable lessons learned	35
Reducing the pressure in pulmonary arterial hypertension: sotatercept, haemodynamics and the right ventricle	34
Fentanyl or Morphine for Persistent Dyspnea in COPD: a multicenter randomised cross-over trial	34
Inhaled treprostinil for interstitial lung disease-associated pulmonary hypertension: a silver lining on a very dark cloud	34
Respiratory support and bronchopulmonary dysplasia in infants born at 22–26 weeks gestation in Sweden, 2004–2007 and 2014–2016	34
Interalveolar pore morphology in (pre-)COPD stages and associations with small airways	34
Now we know: chronic exposure to air pollutants is a risk factor for the development of idiopathic pulmonary fibrosis	33
The longitudinal microbial and metabolic landscape of infant cystic fibrosis: the gut–lung axis	33
Combining digital adherence technology and therapeutic drug monitoring for personalised tuberculosis care	33
Reply: Why fan therapy does not yet demonstrate enhanced training benefits in people with chronic respiratory disease	33
I love you with all my lungs: a viewpoint on communicating effectively and positively about lung health	33
Nasal airway microRNA profiling of infants with severe bronchiolitis and risk of childhood asthma: a multicentre prospective study	33
Relieving dyspnoea through the brain	32
Aspergillussensitisation: an underappreciated treatable trait in airway disease	32
Dyspnoea in acutely ill mechanically ventilated adult patients: an ERS/ESICM statement	32
Impact of elexacaftor/tezacaftor/ivacaftor therapy on lung clearance index and magnetic resonance imaging in children with cystic fibrosis and one or twoF508delalleles	32
Bridging the airway microbiome and targeted therapy in bronchiectasis: multi-omics insights, endotypes and emerging therapies	31
A range of 30–62% of functioning multiciliated airway cells is sufficient to maintain ciliary airway clearance	31
Incidence of interstitial lung abnormalities: the MESA Lung Study	31
Pathogenic variants inCFAP46,CFAP54,CFAP74andCFAP221cause primary ciliary dyskinesia with a defective C1d projection of the central apparatus	31
Quantifying COPD as a risk factor for cardiac disease in a primary prevention cohort	31

Moving the dial on identifying endotypes of asthma from early life	31
Dexamethasone for preterm infants at risk of bronchopulmonary dysplasia: is timing everything?	30
Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studi	30
Reply: Addressing unmeasured confounding and detection bias in dupilumab–lymphoma association	30
Pulmonary hypertension associated with left heart disease	30
Reply: Cognitive behavioural therapy sessions approach ineffective for anxiety and depression in COPD: is the door closed for good?	30
The evidence base for ICS/formoterol maintenance and reliever therapy in severe asthma	30
All roads lead to COPD… or not?	30
What can lockdowns tell us about the underlying causes of asthma exacerbations? A retrospective cohort study	30
Ensuring availability of respiratory medicines in times of European drug shortages	30
NSAID-exacerbated respiratory disease, dupilumab and aspirin tolerance	30
“Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension.” Mark Toshner, Colin Church, Lars Harbaum, et	29
Uptake and 4-week quit rates from an opt-out co-located smoking cessation service delivered alongside community-based low-dose computed tomography screening within the Yorkshire Lung Screening Trial	29
Multi-beat pressure–volume loop-derived right ventricular–pulmonary arterial coupling predicts transplant-free survival in pulmonary arterial hypertension	29
Extracorporeal photopheresis for the prevention of rejection after lung transplantation: a prospective randomised controlled trial	29
Reply: SABRE for airway quantification in idiopathic pulmonary fibrosis: clarifications, limitations, and next steps	29
Tofacitinib in anti-MDA5-positive dermatomyositis-associated interstitial lung disease: a new standard of care emerges	29
Beyond phenotypic differences: integrating clinical pharmacy into precision management of paediatric-onset bronchiectasis	29
Opioids for dyspnoea in interstitial lung disease: does the sequence and timing of therapy matter?	29
Whole lung directed anti-muscarinic therapy improves small airway dysfunction in COPD patients	28
Nebulised liposomal amphotericin-B: a promising strategy for preventing ABPA relapse	28
Up-regulated matrix metalloproteinase activity in soil-transmitted helminth–tuberculosis co-infection is associated with increased lung pathology	28
Genetic associations between serotonin receptor 1F (HTR1F) regulatory variation and sleep apnoea in non-obese individuals: insights from GWAS and eQTL analyses	28
A European multicentre, randomised controlled trial of pirfenidone in bronchiolitis obliterans syndrome after bilateral lung transplantation	28
How bad is your cough? The McMaster Cough Severity Questionnaire as a new tool to measure chronic cough	28
Development and validation of a predictive 6-min walk score in patients with idiopathic pulmonary fibrosis	28
ERJ Podcast December 2023: Year in review	27
List of European Respiratory Journal peer reviewers 2022	27
Eligibility criteria from pharmaceutical randomised controlled trials of idiopathic pulmonary fibrosis: a registry-based study	27
ERJ Podcast July 2023: The HISTORIC study	27
ERS technical standards for using type III devices (limited channel studies) in the diagnosis of sleep disordered breathing in adults and children	27
“From pre-COPD to COPD: a Simple, Low cost and easy to IMplement (SLIM) risk calculator.” M.J. Divo, C. Liu, F. Polverino,et al.Eur Respir J2023; 62: 2300806.	27
Predicting asthma exacerbations: is there utility in noninvasive assessment of distal airway inflammation using multiple flow F ENO	27
Neutrophil elastase-dependent cleavage of LTA4H alters its aminopeptidase activity in cystic fibrosis	27
Low smoking exposure and development and prognosis of COPD over four decades: a population-based cohort study	26
Integrating hot topics and implementation of treatable traits in asthma	26
High prevalence of TSC2 mutations in lung tissue samples from patients with sporadic lymphangioleiomyomatosis	26
Circulating proteomic landscape of lung function	26
ERJ Viewpoint: vascular targeted therapies for fibrotic lung disease – Start of a new era?	26
Pirfenidone and risk of lung cancer development in idiopathic pulmonary fibrosis: a nationwide population-based study	26
Management of pulmonary hypertension in special conditions	25
Phenotyping the responses to systemic corticosteroids in the management of asthma attacks (PRISMA)	25
Clinical trial design, end-points, and emerging therapies in pulmonary arterial hypertension	25
D e novo SRRM2 variants in neuroendocrine cell hyperplasia of infancy and persistent tachypnoea of infancy	25
Decoding the complexity: mechanistic insights into comorbidities in idiopathic pulmonary fibrosis	25
An electrocardiogram-based AI algorithm for early detection of pulmonary hypertension	25
Progressive pulmonary fibrosis: an expert group consensus statement	24
Comment on: Inflammatory plasma protein levels are elevated years before sarcoidosis diagnosis: a nested case–control study in Sweden	24
Reply to: Risk factors for disease progression in fibrotic hypersensitivity pneumonitis	24
Uncovering early COPD? The T-slope as a novel CT biomarker for evaluating airway narrowing	24
Gut microbiota-derived succinate aggravates acute lung injury after intestinal ischaemia/reperfusion in mice	24
ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia	24
Cancer risk associated with alpha-1-antitrypsin deficiency: only large registries will give us the answer	23
Drug-induced lung disease: unwanted collateral damage	23
Is two better than one? Targeted treatment of obstructive sleep apnoea using combination therapy to attack endotypes	23
Reversible carfilzomib-induced pulmonary arterial hypertension: don't take your eyes off the ball!	23
Tailored psychological intervention for anxiety or depression in COPD (TANDEM): a randomised controlled trial	23
The interface in home non-invasive ventilation: is the nasal mask better?	23
Reply to: Insights on the ERS/ESTS statement on the management of pleural infection in adults	23
“Interstitial lung abnormalities are associated with decreased mean telomere length.” R.K. Putman, G.T. Axelsson, S.Y. Ash, et al . <	23
Life between breaths: quality of life in children's interstitial and diffuse lung disease	23
Clinical applications of the 2025 ERS/ATS update of the international multidisciplinary classification of the interstitial pneumonias	23
TB or not TB: does AI have an answer for children?	23
Heart or lungs? Why not both!	23
The ERS PROFILE.net Clinical Research Collaboration is dedicated to the set-up of an academic network to enhance imaging-based management of progressive pulmonary fibrosis	23
AMR-Lung: a European Clinical Research Collaboration on antimicrobial resistance in chronic lung disease	23
Building translational bridges in idiopathic pulmonary fibrosis research: from epithelial dysfunction to dysregulated macrophage polarisation and fibrogenesis	23
The causal relationship between gastro-oesophageal reflux disease and idiopathic pulmonary fibrosis: a bidirectional two-sample Mendelian randomisation study	22
Saline at lower tonicity in cystic fibrosis (SALTI-CF) trial comparing 0.9%versus3%versus6% nebulised saline	22
ERJ Podcast April 2026: Use of spirometry to define airflow obstruction and diagnose COPD	22
Sequential multimodal therapy in chronic thromboembolic pulmonary hypertension with mixed anatomical lesions: a proof of concept	22
Characteristics and outcomes of patients developing pulmonary hypertension associated with proteasome inhibitors	21
Increasing physical activity in severe asthma: a systematic review and meta-analysis	21
Deep phenotyping of unaffected carriers of pathogenicBMPR2variants screened for pulmonary arterial hypertension	21
Artificial intelligence in idiopathic pulmonary fibrosis: advances, challenges and future directions	21
“Spatial transcriptomics for respiratory research and medicine.” S. Curras-Alonso, J. Soulier, T. Walter, et al . Eur Respir J	21
How do people with COPD walk? A European study on digitally measured real-world gait	21
Genome-wide association study of susceptibility toPseudomonas aeruginosainfection in cystic fibrosis	21
Latent COPD: a proposed new term in the disease nomenclature	21
Endothelial cells in pulmonary fibrosis: more than a bystander	20
Joint statement from GOLD/GLI regarding the use of spirometry to define airflow obstruction and diagnose COPD	20
Right heart function during and after pregnancy in women with pulmonary arterial hypertension	20
ERS/ESTS/ESTRO/ESR/ESTI/EFOMP statement on management of incidental findings from low dose CT screening for lung cancer	20
The paradox of the safer cigarette: understanding the pulmonary effects of electronic cigarettes	20
“Post tuberculosis”: the urgent need for inclusion of lung health outcomes in tuberculosis treatment trials	20
The rat takes the cheese: a novel model of CFTR-dependent chronic bacterial airway infection	20
CPAP resumption after a first termination and impact on all-cause mortality in France	20
Associations of combined phenotypic ageing and genetic risk with incidence of chronic respiratory diseases in the UK Biobank: a prospective cohort study	20
From small to big, using microRNA profiling to investigate infant origins of childhood asthma	19
Reply to: Critique of logistic regression in analysing treatment response in severe eosinophilic asthma	19
Bronchiectasis in low- and middle-income countries: the importance of the wider view	19
Renal function dynamics in pulmonary hypertension trials: less than anticipated	19
Clarification of author disclosures for four ERJ articles	19
Neutrophils in pleural infection: untapped potential for targeted therapeutics	19
Comment on: Revised ISHAM-ABPA working group clinical practice guidelines for diagnosing, classifying and treating allergic bronchopulmonary aspergillosis/mycoses	19